In partnership with

  • Conferences
  • Disease Areas
  • News
  • Articles
  • Contact
    • Highlights from

    ACC 2019

    American College of Cardiology Annual Scientific Session & Expo

    New Orleans 16-18 March 2019

    Presented at the 68th Annual Scientific Session are the latest late-breaking trial results on heart failure and cardiomyopathies, interventional cardiology, and prevention. Read the full peer-reviewed Conference Report.

    View the eBook of the full conference report.

    Articles

    Letter from the Editor

    article thumbnail

    Letter from the Editor

    2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease

    2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease

    Acute and Stable Ischaemic Heart Disease

    Patients with polyvascular disease significantly undertreated with lipid lowering therapies

    DECLARE TIMI-58 trial shows benefits of dapagliflozin in high-risk subgroups

    Superior outcomes of DES compared with BMS in very elderly population

    Arrhythmias and Clinical Electrophysiology

    Diagnosing cardiac sarcoidosis with endomyocardial biopsies

    Substantial impact of temporary interruptions of warfarin versus DOAC

    Less bleeding and fewer hospitalisations with antithrombotic regimen with apixaban without aspirin

    Smartwatch can detect atrial fibrillation with high degree of accuracy

    Congenital Heart Disease

    Higher incidence arrhythmia post-percutaneous closure of secundum ASD in patients >60 years

    Unplanned hospital readmission is common after congenital cardiac surgery

    Heart Failure and Cardiomyopathies

    Frequent use of beta-blocker after HFpEF hospitalisations in elderly patients without compelling indications

    BNP still a reliable prognostic marker before and during sacubitril/valsartan treatment

    High 5-year survival rates for older HF patients without initial severe comorbidity

    Pulmonary Arterial Hypertension and Venous Thromboembolism

    Apixaban is safe and effective in real-world setting for treatment of venous thromboembolism

    Treatment patterns PAH have changed recently

    Interventional Cardiology

    TAVR superior and non-inferior to SAVR in low-risk patients

    Immediate angiography not better than delayed angiography in non-STEMI cardiac arrest patients

    Ticagrelor monotherapy safe after dual antiplatelet therapy

    P2Y12 inhibitor monotherapy is a novel antiplatelet strategy after short duration DAPT

    Vascular Medicine

    Similar MACE rates but higher all-cause mortality in PAD patients with diabetes

    Lower rates stroke/SE with DOACs in frail non-valvular AF patients

    Similar rates of stroke/SE associated with DOAC vs warfarin use in obese non-valvular AF patients: Results from an observational registry

    Convincing evidence of the role of icosapent in reducing subsequent CV events

    Clopidogrel monotherapy after 1-month DAPT may be beneficial in stent patients

    Early discharge and home treatment feasible for low-risk pulmonary embolism patients

    The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.

    BACK TO TOP